Prof. Dominique Le Guludec
EANM Congress President 2013
Prof. Dr. Fred Verzijlbergen
EANM President 2013-2014
The European Association of Nuclear Medicine
(EANM) recently held its annual congress in Lyon, France. HealthManagement caught
up with EANM President, Professor Fred Verzijlbergen (FV), and Congress
President 2013, Professor Dominique Le Guludec (DLG), to learn their thoughts
on the congress, the role of the EANM and the direction of nuclear medicine.
For more information on the EANM and EANM 2014 in Gothenburg, Sweden, please visit http://www.eanm.org and https://www.facebook.com/officialEANM.
Watch the full interview at http://www.youtube.com/user/officialEANM.
For any questions, please contact: Agnes Falkner | EANM Project & Communications Manager | firstname.lastname@example.org
What does the annual congress have to offer?
DLG: The annual congress is the most importantevent each year for our community, because it’s the only place where everybody meets. Everyone involved in the field of nuclear medicine – doctors, technologists, physicists, radiopharmacists, industry – all partners are there. There are plenty of sessions – scientific sessions, CME sessions, sessions for technologists, symposia and plenaries with very famous lecturers. There is also a big industry exhibition, and an opportunity to have fun. All CME sessions are online after the meeting, at http://eLearning.eanm.org/, so people who couldn’t come can also enjoy them. That’s important for our community.
FV: People come for the science. They want to learn about the newest ideas and innovations, but they also want to meet colleagues and to hear about their ideas on how to treat patients and how to perform diagnostic procedures. The focus is on education and innovation but also to an extent on meeting friends and having an enjoyable time together.
What were the highlights of EANM 2013 for you?
DLG: The increased number of abstracts submitted on PET. New tracers and radiopharmaceuticals are of huge importance, as is the use of bioimaging in the management of therapy in all fields, including oncology, cardiology and neurology.
FV: As President I don’t get much time to hear the presentations, so my highlights were meeting colleagues and friends, not only from EANM but also from other countries – the U.S., India, Japan – and planning for the future in relation to education, training and research.
More highlights of EANM 2013 in Lyon at http://www.flickr.com/photos/officialeanm/
This is the second time the congress has been in France, and the first time in Lyon. Please tell us about the state of nuclear medicine in France.
DLG: Nuclear medicine in France is quite a big specialty. We have 217 nuclear medicine departments, 468 gamma cameras, one-third of them equipped with CT, over 115 PET-CT machines and 31 cyclotrons, including four cyclotrons only for research. There is extensive research on bioimaging in France, with more than 80 groups and over 1000 people involved. During the past 12 years more than 15,000 papers have been published in imaging journals, with a quarter on nuclear medicine. Progress in the field is being fostered by France Life Imaging (FLI), a project to establish a coordinated network of in vivo biomedical imaging research throughout France (see http://its.aviesan.fr).
Why did EANM change its logo and add the slogan "biomedical imaging and therapy for personalized healthcare"?
FV: It emphasises better what nuclear medicine is doing. Many people are unclear about the nature of nuclear medicine – they have fantasies about it and think terrible things – but the term “biomedical imaging” emphasises that we are imaging a biological process. We are able to visualise what is happening in the body in healthy people, but also in people who are ill. If we can image that, we can also follow the process and visualise what’s happening during treatment. It gives us a lot of opportunities to really attract attention to the biological process in the body. This is very interesting because nowadays we are all focussing on personalised medicine in many ways, which means that we are trying to find medications and treatments which are dedicated to a specific situation for a person or a small number of patients with a particular disease. If you are able to focus on that, have the means to visualise that, then it makes you very strong.
Please tell us more about the EANM.
FV: The heart of the EANM is within training and education. We have a European School of Nuclear Medicine (ESNM) and organise training in Vienna, which includes all kinds of courses for physicians who want to be educated in nuclear medicine, together with radiation oncologists. In addition, we organise courses in Central and Eastern Europe. That is the main task of the EANM: to educate and train our young residents, as well as older medical specialists who want to improve in their work. We also have the scientific side of the EANM, with a lot of scientific committees working on different issues. Then there are organisational matters, including making ourselves visible to other organisations – that is more about the future.
What barriers have you encountered inside and outside the EANM?
FV: There are not so many barriers. There were issues in the last few years about collaboration with radiologists, and some authorities in Europe are not sufficiently aware of what nuclear medicine is doing, but beyond that there are no major obstacles. There are, however, some minor issues like radiation protection. We have to be very aware that we use a small amount of radiation and have to defend that. We have the knowledge and are able to demonstrate and defend what we are doing.
What are the recent developments in the relationship between nuclear medicine and radiology?
FV: We can collaborate with radiology. A younger generation is coming through which is more interested in education and cooperation, including finding the best ways of studying and imaging particular diseases. Things are definitely improving, and in the next few years there will be more collaboration.
What will be the next task you have to cope with after the congress?
FV: We need funding. The EU has granted more than €63 billion for research, and nuclear medicine needs a lot of money for research. We want to find partners for the research we want to perform – to find better radiopharmaceuticals and improve in the area of personalised medicine (see research 4 Life http://earl.eanm.org). These partners could be from other clinical fields, for instance cardiology and oncology, but also from areas like radiation oncology and radiology. The choice of partner will vary depending on the issue we want to study.
What are the challenges for nuclear medicine in Europe outside the EANM?
FV: The most important one for me is making ourselves visible. The EU should know that if they discuss personalised medicine and biomedical imaging, they have to go to the EANM. It is not easy to ensure such visibility because most authorities are not aware of nuclear medicine, and we therefore have to go to the European committee, the Parliament, and find those bodies that are interested in this. This is a very important issue for next year.
What attracted you to nuclear medicine as a specialty?
DLG: I used to be a cardiologist. I moved to nuclear medicine because I thought it was really innovative and had a lot of new ideas and tools for healthcare. Nuclear medicine represents biology in vivo. That’s a tremendous field of improvement of healthcare. It has fulfilled all my expectations.
FV: I trained as a clinical doctor, in internal medicine. At the end of my training I started working in a department of nuclear medicine, for research. I added nuclear medicine training to my internal medicine training, and was able to work in a hospital where I could spend time as a specialist in internal medicine for one day a week and the rest of the time in nuclear medicine, as well as doing some scientific work. For me that was the ideal combination – see patients, do research and work in a laboratory facility. It’s an absolutely fascinating and always thrilling combination. It’s lived up to my expectations.
How important is it for healthcare management to be more efficient in regards to nuclear medicine?
DLG: Management is important in all fields of medicine. I am chief of a department and chief of a research group, so there’s a lot of management of human and financial resources and management to ensure compliance with laws. We have a lot of rules in nuclear medicine in relation to radiation protection, the use of radiation, the role of radiopharmacy and so on. A large part of our work is management, so it’s important to be efficient in the use of public resources.
FV: Nowadays, because of economic problems, resources for hospitals are decreasing everywhere in Europe. What you see is that doctors are performing diagnostic procedures in a more stringent way. They think twice before they ask the nuclear physician to perform the procedure. The result is that we perform fewer studies. In many situations that is good because we save money and limit radiation to the patient, but handling this situation is also a challenge for the hospital and the department of nuclear medicine. I think we are approaching a point where we are able to work very efficiently and save as much money as we can, while also improving the quality of procedures. That involves management at the hospital and the nuclear medicine department level. We have to spend a lot of time on that.